Thrombocytopenia – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Thrombocytopenia is defined as the deficiency of platelets (thrombocytes) that increases the risk of bleeding. It occurs when the bone marrow produces insufficient platelets or when an excessive number of platelets are destroyed or accumulated within an enlarged spleen. In this condition, the platelet count of patients drops down to less than 150 x 103 per μL. Typically, platelet counts higher than 50 x 109 per L do not lead to clinical problems unless platelet dysfunction co-exists with the low count; instead, they are picked up on a routine complete blood count. It is classified as Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Drug-Induced Thrombocytopenia, and others based on etiology. Immune (Idiopathic) Thrombocytopenic Purpura is an acquired immune-mediated disorder that occurs due to the destruction of premature platelets. It is characterized by minimal bleeding or severe hemorrhage such as mucosal, intracranial, gastrointestinal, and genitourinary. Thrombotic Thrombocytopenic Purpura occurs due to the formation of abnormal blood clots by platelets in the blood vessels, which results in low platelet counts among the patients. Drug-induced Thrombocytopenia occurs due to the long-term use of the drugs resulting in the formation of blood clots among the patients. Drugs attack and destroy blood platelets, resulting in acute and severe bleeding, bone marrow suppression, or pressuring the megakaryocyte in producing Thrombocytopenia.

The prevalence of ITP has been reported to be ranging from 4.5 to 10.5 cases per 100,000 persons in adults and 4.6 cases per 100,000 in children

 

The competitive landscape of Thrombocytopenia includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Thrombocytopenia across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Thrombocytopenia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Thrombocytopenia – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Rozanolixizumab           UCB Pharma    Phase 3

2          Romiplostim      Kyowa Hakko Kirin China Pharmaceutical Co., LTD.            Phase 2

3          Efgartigimod     argenx  Phase 3

4          Avatrombopag  Dova Pharmaceuticals   Phase 3

5          Romiplostim      Amgen  Phase 3

6          Hetrombopag    Jiangsu HengRui Medicine Co., Ltd.       Phase 3

7          NewGam          Octapharma      Phase 3

8          avatrombopag   Eisai Inc.          Phase 2

9          SKI-O-703        Oscotec Inc.     Phase 2

10        HMPL-523        Hutchison Medipharma Limited  Phase 3

Continued